[{"orgOrder":0,"company":"AdipoPharma","sponsor":"Newton Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Series A Financing","leadProduct":"PATAS","moa":"","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AdipoPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AdipoPharma \/ Newton Biocapital","highestDevelopmentStatusID":"4","companyTruncated":"AdipoPharma \/ Newton Biocapital"},{"orgOrder":0,"company":"AdipoPharma","sponsor":"Newton Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Funding","leadProduct":"PATAS","moa":"","graph1":"Technology","graph2":"Approved","graph3":"AdipoPharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"AdipoPharma \/ Newton Biocapital","highestDevelopmentStatusID":"12","companyTruncated":"AdipoPharma \/ Newton Biocapital"}]

Find Clinical Drug Pipeline Developments & Deals by AdipoPharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : The funding will enable AdipoPharma to accelerate its clinical development of a first-in-class compound, PATAS, that directly targets insulin resistance, the root cause of Type 2 diabetes.

                          Brand Name : PATAS

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          November 11, 2024

                          Lead Product(s) : PATAS

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Newton Biocapital

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : AdipoPharma uses a novel approach to treating Type 2 diabetes. AdipoPharma’s drug, PATAS, treats insulin resistance, the root cause of Type 2 diabetes. PATAS has been designed while working on fat cells known as adipocytes.

                          Brand Name : PATAS

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          January 23, 2023

                          Lead Product(s) : PATAS

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Newton Biocapital

                          Deal Size : Undisclosed

                          Deal Type : Series A Financing

                          blank